Search | Clinical Trials Finder

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions: DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy; Biological · Radiation · Drug
Lead sponsor: DEKA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: ASA404, Placebo, docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 88
States / cities: Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more

Conditions: Lung Neoplasms, Non-Small Cell Lung Cancer
Interventions: Irinotecan, Cisplatin; Drug
Lead sponsor: Leo W. Jenkins Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Lung Cancer
Interventions: Induction Carboplatin, Induction Paclitaxel, Resection, Consolidation Carboplatin, Radiation Therapy, Consolidation Paclitaxel; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more

Conditions: Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
Interventions: AMG 510; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
U.S. locations: 30
States / cities: Huntsville, Alabama • Anchorage, Alaska • Chandler, Arizona + 27 more

Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1); Drug · Procedure
Lead sponsor: Ascendis Pharma Oncology Division A/S; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Paclitaxel / Carboplatin, bavituximab; Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Chandler, Arizona • Jonesboro, Arkansas • Whittier, California + 14 more

Conditions: Non-small Cell Lung Cancer
Interventions: Docetaxel, LY2181308; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Interventions: CTX-471, Pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 20
States / cities: Fresno, California • Hollywood, Florida • Orlando, Florida + 17 more

Conditions: Locally Advanced or Metastatic NSCLC
Interventions: PBF-1129; Drug
Lead sponsor: Palobiofarma SL; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed; Drug
Lead sponsor: BlossomHill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: Dostarlimab, Belrestotug, Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more

Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Interventions: Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions: inupadenant, Placebo, Carboplatin, Pemetrexed; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Tampa, Florida

Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Esophageal, Toxicity
Interventions: Manganese Superoxide Dismutase Plasmid Liposome, carboplatin, paclitaxel, Radiation Therapy; Genetic · Drug · Radiation
Lead sponsor: Joel Greenberger; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: daraxonrasib, docetaxel; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 45
States / cities: Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 38 more

Conditions: Squamous Non Small Cell Lung Cancer
Interventions: HLX10, carboplatin and nab paclitaxel, Placebo; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 13
States / cities: Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more

Conditions: NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Interventions: YH42946; Drug
Lead sponsor: Yuhan Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 28
States / cities: Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more

Conditions: Carcinoma
Interventions: osimertinib, savolitinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Lung Cancer
Interventions: Radiation therapy, Observation; Radiation · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Chicago, Illinois + 10 more

Search by objective public record fields.

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Expanded Access of Sotorasib

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

PBF-1129 in Patients With NSCLC

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Locally Advanced NSCLC Hyperfractionated RT

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer